N-acetyl cysteine for people with diabetic retinopathy
Tests N-acetyl cysteine in adults with type 2 diabetes and diabetic retinopathy.
Plain-language title generated from the registry record
Registry title: To Evaluate the Efficacy and Safety of N-acetyl Cysteine Administration in Patients With Diabetic Retinopathy
Key facts
- Where
- Cairo, EgyptSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who have mild to moderate diabetic retinopathy. It tests N-acetyl cysteine 1200mg.
- Age
- Over 18 and under 70 years.
- Sex
- All sexes can join.
- Disease stage
- Mild to moderate diabetic retinopathy in type 2 diabetes.
- Earlier treatment
- People with previous surgical or laser treatment cannot join. People using antioxidants cannot join. Systemic anti-VEGF or pro-VEGF treatment within 4 months before randomization is not allowed.
- Biomarker or test result
- HbA1C less than 10% (86 mmol/mol). FBG less than 240 mg/dl. Body mass index (BMI) less than 40 kg/m2.
Main reasons for not taking part
- Any other eye condition besides diabetic retinopathy
- Previous surgical or laser treatment
- Pregnant or breastfeeding
- Severe liver or renal disease
- Drug or alcohol abuse, or malignancies
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07634991, who can take part
Where in Egypt
- National Institute of Diabetes and Endocrinology.Cairo, EgyptTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ain Shams University
- Trial code
- NCT07634991
- Record updated
- 9 June 2026
- Original description
N-acetylcysteine (NAC) emerges as a crucial factor in mitigating oxidative stress and inhibiting vascular endothelial activation in diabetic patients, through its effect on VEGF expression as VEGF is involved in the development of diabetic microvascular complications through the promotion of retinal angiogenesis and increased vascular permeability.Read full original descriptionShow less
Effect of N-Acetyl Cysteine on Oxidative Stress and Clinical Outcome of Patients With Diabetic Retinopathy
N-acetylcysteine (NAC) emerges as a crucial factor in mitigating oxidative stress and inhibiting vascular endothelial activation in diabetic patients, through its effect on VEGF expression as VEGF is involved in the development of diabetic microvascular complications through the promotion of retinal angiogenesis and increased vascular permeability.
It was reported in the literature that NAC administration was safe in several studies. It was shown that the dose of 1200 mg is safe and effective.
To the best of our knowledge, the present study is the first to be designed to evaluate the effect of N-acetyl cysteine on diabetic retinopathy in type 2 diabetic patients.
Inclusion: Patients with type 2 diabetes mellitus; Patients with mild to moderate degrees of diabetic retinopathy; Patients over the age of 18 and under the age of 70 years; Patients who voluntarily give their informed consent; HbA1C (glycosylated hemoglobin) less than 10%; FBG less than 240 mg/dl; Body mass index (BMI) less than 40 kg/m2.
Exclusion: • Patients with any other ophthalmologic conditions than diabetic retinopathy; Patients with previous surgical or laser treatment; Pregnant or breastfeeding patients; Patients using antioxidants; Systemic anti-VEGF or pro-VEGF treatment within 4 months before randomization; Patients who are currently participating in other clinical trials; Severe liver or renal disease, (AST or ALT >3 times ULN or Total bilirubin >3 times ULN), (CrCl< 60 ml/min); Current history of drug or alcohol abuse Malignancies.